Hol
Well-known
The sudden ouster this week of Dr. Vinay Prasad from the top vaccine post at the U.S. Food and Drug Administration (FDA) followed directly on the heels of Prasad’s decision to pull a profitable gene therapy from the market
The decision provoked attacks from The Wall Street Journal’s Allysia Finley and Bob Goldberg at The Center for Medicine in the Public Interest. Both accused Prasad of serving as a “one-man death panel” for threatening to revoke access to medicine, investigative journalist Lee Fang reported.
In July, the FDA halted the clinical use of Sarepta Therapeutics’ drugElevidys, used to treat Duchenne muscular dystrophy, following the deaths of three clinical trial participants.
FDA leadership met with Sarepta on July 18, instructed the company to halt all clinical trials and asked it to voluntarily stop all shipments of the drug. The company initially refused to halt shipments, according to the FDA, but eventually stopped shipping the drug on July 22.
childrenshealthdefense.org
The decision provoked attacks from The Wall Street Journal’s Allysia Finley and Bob Goldberg at The Center for Medicine in the Public Interest. Both accused Prasad of serving as a “one-man death panel” for threatening to revoke access to medicine, investigative journalist Lee Fang reported.
In July, the FDA halted the clinical use of Sarepta Therapeutics’ drugElevidys, used to treat Duchenne muscular dystrophy, following the deaths of three clinical trial participants.
FDA leadership met with Sarepta on July 18, instructed the company to halt all clinical trials and asked it to voluntarily stop all shipments of the drug. The company initially refused to halt shipments, according to the FDA, but eventually stopped shipping the drug on July 22.

Are Pharma Lobbyists Behind Vinay Prasad’s Ouster from FDA?
Evidence suggests that some journalists, lawmakers and spokespeople who publicly attacked Prasad and called for his ouster have ties to Sarepta Therapeutics, maker of the drug Elevidys. Prasad moved to pull the drug from the market last month.
